Business Standard

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

SI Team  |  Mumbai 

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

RECOMMENDED FOR YOU

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

image

LIVE MARKET

BSE 25201.90

-562.88 (-2.18 %)

NSE 7655.05

-167.95 (-2.15%)

Widgets Magazine

STOCK WATCH

Company Price() Chg(%)
Ent.Network 655.60 7.67
Goldline Intl. 194.00 4.81
Jyothy Lab. 320.80 4.73
PMC Fincorp 1.63 4.49
Sun TV Network 387.30 4.00
> More on BSE Gainers
Company Price() Chg(%)
Ent.Network 663.05 8.11
Amtek Auto 32.80 4.13
Sun TV Network 387.65 4.04
Jyothy Lab. 319.90 3.98
La Opala RG 589.70 3.91
> More on NSE Gainers
Company Price() Chg(%)
NCC 58.15 -12.23
Financial Tech. 99.95 -11.55
Welspun Corp 100.55 -8.76
Lycos Internet 23.50 -7.84
H D I L 57.00 -7.77
> More on BSE Gainers
Company Price() Chg(%)
NCC 58.10 -12.04
Financial Tech. 100.10 -11.14
Welspun Corp 100.20 -9.36
Himatsing. Seide 178.65 -7.86
H D I L 57.00 -7.62
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price